Skip to content

Efficacy Study for SD Device

Efficacy Study of SD Device for Overweight and Obesity Treatment

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01534325
Enrollment
150
Registered
2012-02-16
Start date
2012-07-31
Completion date
2016-12-31
Last updated
2016-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Overweight

Brief summary

The purpose of this study is to determine whether the SD unique device is effective in treatment of overweight and obesity.

Detailed description

Obesity and Overweight had become the number 1 health concern of the modern world. Over 1 Billion people worldwide are overweight or obese. Those who suffer from overweight or obesity are exposed to other severe illnesses such as: diabetes, cardiovascular disease and cancer. Only few drugs and surgeries are currently available as approved treatments for those who wish to reduce weight. The purpose of this study is to determine whether the SD unique medical device, is effective in treatment of overweight and obesity.

Interventions

DEVICESD

The participants in the study receive basic nutrition guidance by MD and clinical dietician and make daily use of the device under study (called SD). During the 13 weeks study period, the participants get to meet clinical dietician/MD once in every 2 weeks for guidance and supervision and for on -going monitoring of physical parameters such as body weight and waist circumference. The use of the SD device is done by study participants during the day every day throughout the study period. The device under study can be easily used by the participants themselves in their regular environment and does not require professional assistance. The device under study is expected to affects the satiety, energy homeostasis and metabolic control centers in the brain and by that to reduce food intake and lead to weight loss. The device under study is a device- not a medication and not a surgical procedure, and it does not involve any of such elements.

DEVICEControl

The participants in the Control arm of the study receive basic nutrition guidance by MD and clinical dietician and make daily use of the placebo. During the 13 weeks study period, the participants get to meet clinical dietician/MD once in every 2 weeks for guidance and supervision and for on -going monitoring of physical parameters such as body weight and waist circumference. The use of the placebo is done by the control study participants during the day every day throughout the study period. The placebo can be easily used by the participants themselves in their regular environment and does not require professional assistance.

Sponsors

Beck Medical Ltd.
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* BMI 30-41.99 * AGE 18-65 years

Exclusion criteria

* Pregnant Women, * Type I and II diabetes, * People with disfunctioning of thyroid gland * Hypertension

Design outcomes

Primary

MeasureTime frameDescription
Change from Baseline in Body Weightonce in every two weeks up to 13 weeks for each participantEach participant's body weight will be measured at his/her beginning of the trial. This measure will become the participant's body weight base-line. Once in every 2 weeks the body weight will be taken again and will be compared to base-line and to previous body weight measures of the participant taken during the study.

Secondary

MeasureTime frameDescription
Change from Baseline in Waist Circumferenceonce in every two weeks up to 13 weeks for each participantEach participant's Waist circumference will be measured at his/her beginning of the trial. This measure will become the participant's Waist circumference base-line. Once in every 2 weeks the Waist circumference will be taken again and will be compared to base-line and to previous Waist circumference measures of the participant taken during the study.

Countries

Israel

Contacts

Primary ContactBeck Medical
adva@beckmedical.com+972-4-62890779

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026